1543 related articles for article (PubMed ID: 15991605)
1. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
[TBL] [Abstract][Full Text] [Related]
2. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
Looney RJ
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
[TBL] [Abstract][Full Text] [Related]
3. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
Dörner T
J Rheumatol Suppl; 2006 May; 77():3-11. PubMed ID: 16652439
[TBL] [Abstract][Full Text] [Related]
4. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice.
Falcone M; Lee J; Patstone G; Yeung B; Sarvetnick N
J Immunol; 1998 Aug; 161(3):1163-8. PubMed ID: 9686575
[TBL] [Abstract][Full Text] [Related]
5. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.
Mease PJ
J Rheumatol; 2008 Jul; 35(7):1245-55. PubMed ID: 18609733
[TBL] [Abstract][Full Text] [Related]
6. B cell-targeted therapy in diseases other than rheumatoid arthritis.
Looney RJ
J Rheumatol Suppl; 2005 Feb; 73():25-8; discussion 29-30. PubMed ID: 15693113
[TBL] [Abstract][Full Text] [Related]
7. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
Eisenberg R; Albert D
Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune disorders in diabetes.
Boitard C; Debray-Sachs M; Bach JF
Adv Nephrol Necker Hosp; 1986; 15():281-305. PubMed ID: 3082114
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD20 treatment prolongs syngeneic islet graft survival and delays the onset of recurrent autoimmune diabetes.
Hu C; Deng S; Wong FS; Wen L
Ann N Y Acad Sci; 2008 Dec; 1150():217-9. PubMed ID: 19120299
[TBL] [Abstract][Full Text] [Related]
10. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
Stübgen JP
J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
[TBL] [Abstract][Full Text] [Related]
11. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice.
Serreze DV; Fleming SA; Chapman HD; Richard SD; Leiter EH; Tisch RM
J Immunol; 1998 Oct; 161(8):3912-8. PubMed ID: 9780157
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.
Liossis SN; Sfikakis PP
Clin Immunol; 2008 Jun; 127(3):280-5. PubMed ID: 18337174
[TBL] [Abstract][Full Text] [Related]
13. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.
Kazkaz H; Isenberg D
Curr Opin Pharmacol; 2004 Aug; 4(4):398-402. PubMed ID: 15251135
[TBL] [Abstract][Full Text] [Related]
14. The T cell receptor in autoimmune diseases.
Bluestone JA; Spencer C; Hirsch R
J Rheumatol Suppl; 1992 Apr; 33():75-7. PubMed ID: 1534379
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of anti-CD20 "what do B-cells do?".
Eisenberg R; Looney RJ
Clin Immunol; 2005 Dec; 117(3):207-13. PubMed ID: 16169773
[TBL] [Abstract][Full Text] [Related]
16. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
Perosa F; Prete M; Racanelli V; Dammacco F
J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920
[TBL] [Abstract][Full Text] [Related]
17. B cells move to centre stage: novel opportunities for autoimmune disease treatment.
Browning JL
Nat Rev Drug Discov; 2006 Jul; 5(7):564-76. PubMed ID: 16816838
[TBL] [Abstract][Full Text] [Related]
18. IL-4 triggers autoimmune diabetes by increasing self-antigen presentation within the pancreatic Islets.
Falcone M; Yeung B; Tucker L; Rodriguez E; Krahl T; Sarvetnick N
Clin Immunol; 2001 Feb; 98(2):190-9. PubMed ID: 11161975
[TBL] [Abstract][Full Text] [Related]
19. CD20: a target antigen for immunotherapy of autoimmune diseases.
Perosa F; Favoino E; Caragnano MA; Prete M; Dammacco F
Autoimmun Rev; 2005 Nov; 4(8):526-31. PubMed ID: 16214090
[TBL] [Abstract][Full Text] [Related]
20. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis.
Taylor RP; Lindorfer MA
Nat Clin Pract Rheumatol; 2007 Feb; 3(2):86-95. PubMed ID: 17299446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
